Michael Conroy, MD
Dermatology · Dublin, OHNPI 1003891052
Payments from drug & device makers
Across 338 payments — averaging $45.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10K
- AbbVie$2K
- Novartis$728
- Sanofi$475
- Galderma Laboratories, L.p.$371
- Prugen, Inc. Pharmaceuticals$348
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$9,60063%
- Food & beverage$5,53636%
- Education$861%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $9,719 |
| AbbVie | 123 | $1,835 |
| Novartis | 49 | $728 |
| Sanofi | 33 | $475 |
| Galderma Laboratories, L.p. | 26 | $371 |
| Prugen, Inc. Pharmaceuticals | 8 | $348 |
| Johnson & Johnson | 14 | $287 |
| Regeneron Healthcare Solutions, Inc. | 8 | $252 |
| Dermavant Sciences, Inc. | 15 | $218 |
| Incyte Corporation | 4 | $187 |
| Lilly USA, LLC | 11 | $171 |
| E.r. Squibb & Sons, L.L.C. | 6 | $87 |
| Sun Pharmaceutical Industries Inc. | 5 | $79 |
| Verrica Pharmaceuticals Inc. | 3 | $76 |
| Organon | 5 | $71 |
| Arcutis Biotherapeutics, Inc. | 2 | $46 |
| Almirall LLC | 2 | $40 |
| Journey Medical Corporation | 3 | $34 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $34 |
| LEO Pharma Inc. | 1 | $26 |
| Genentech USA, Inc. | 2 | $25 |
| VYNE Pharmaceuticals Inc. | 1 | $24 |
| EPI Health, LLC | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| Biofrontera Inc. | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $12 |
How this compares
$15,222 in reported general payments places this provider in the 80th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 23 | $497,896 |
| Humira PenAdalimumab | 13 | $90,454 |
| Triamcinolone Acetonide | 185 | $2,879 |
| Desoximetasone | 50 | $2,686 |
| Ketoconazole | 152 | $1,918 |
| Clobetasol Propionate | 57 | $1,884 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 19 | $1,676 |
| Fluocinonide | 30 | $1,259 |
| Doxycycline Hyclate | 54 | $1,113 |
| Metronidazole | 26 | $1,065 |
| Clindamycin Phosphate | 17 | $810 |
| Minocycline Hcl | 34 | $790 |
| Hydrocortisone | 49 | $561 |
| Spironolactone | 29 | $356 |
| MethotrexateMethotrexate Sodium | 14 | $237 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Dublin
- Matthew ZirwasBexley$7.4M
- Neil KormanCleveland$6M
- Jeffrey TraversDayton$4.7M
- Jennifer NashWesterville$4M
- Jessica KaffenbergerColumbus$3.2M
- Rocco SerraoDayton$3M
- Patrick ShannonBoardman$2M
- George DrewMarion$2M
- Benjamin BoguckiColumbus$2M
- Michelle ChambersColumbus$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.